Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

BACKGROUND: Carbonic anhydrase 9 (CA9) is a marker for hypoxia and acidosis, which is linked to a poor prognosis in human tumors. The purpose of this comparative analysis was to evaluate whether CA9 and VEGF expression are associated with survival outcomes in patients with metastatic colorectal canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Yong Sang, Cho, Hyeon Jin, Kim, Sun Young, Jung, Kyung Hae, Park, Ji Won, Choi, Hyo Seong, Oh, Jae Hwan, Kim, Byung Chang, Sohn, Dae Kyung, Kim, Dae Yong, Chang, Hee Jin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719665/
https://www.ncbi.nlm.nih.gov/pubmed/19619339
http://dx.doi.org/10.1186/1471-2407-9-246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719665/
https://www.ncbi.nlm.nih.gov/pubmed/19619339
http://dx.doi.org/10.1186/1471-2407-9-246

Ejemplares similares